Login to Your Account

'Not a Typical Shell Merger'

IPOs Hot, but Ocera Chooses Reverse Merger to Go Public

By Brian Orelli
Contributing Writer

Monday, July 22, 2013

The IPO window has turned into a sliding glass door with biotechs seizing the opportunity to tap the public markets. According to BioWorld Snapshots, 19 biotechs have hit the U.S. markets since the beginning of the year. And there are quite a few others building their books hoping to price in the coming weeks.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription